Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458559 | 0.97 | ROCK2 (0.41) | HPGDTSHRROCK2ALDH1A1MAPT | |
| SCHEMBL17458515 | 0.92 | POLB (0.37) | ROCK2LMNAMTORACHE | |
| SCHEMBL17458578 | 0.92 | ROCK2 (0.40) | HPGDTSHRROCK2ALDH1A1LMNA | |
| SCHEMBL17458532 | 0.89 | HTR6 (0.41) | HPGDALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL17458573 | 0.88 | ROCK2 (0.39) | ROCK2LMNAMTORACHE | |
| SCHEMBL17464722 | 0.88 | ACHE (0.39) | HPGDTSHRALDH1A1LMNAMAPT | |
| SCHEMBL17464732 | 0.87 | MTOR (0.41) | ROCK2MTORACHE | |
| SCHEMBL17464741 | 0.86 | LRRK2 (0.43) | ROCK2MTOR | |
| SCHEMBL17464715 | 0.85 | MTOR (0.39) | ROCK2MTORACHE | |
| SCHEMBL17458593 | 0.85 | HTR6 (0.44) | ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | claimed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | claimed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | claimed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3172195-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | Innov17 LLC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2016014910-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | HPGD 2747/4885TSHR 96/4885ROCK2 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.